Your browser doesn't support javascript.
loading
Expression profile of microrna-145 in urothelial bladder cancer
International Braz J Urol; Dip, Nelson; Reis, Sabrina T.; Srougi, Miguel; Dall'oglio, Marcos F.; Leite, Katia R. M..
  • Dip, Nelson; University of Sao Paulo Medical School. Urology Department. Laboratory of Medical Investigation.
  • Reis, Sabrina T.; University of Sao Paulo Medical School. Urology Department. Laboratory of Medical Investigation.
  • Srougi, Miguel; University of Sao Paulo Medical School. Urology Department. Laboratory of Medical Investigation.
  • Dall'oglio, Marcos F.; University of Sao Paulo Medical School. Urology Department. Laboratory of Medical Investigation.
  • Leite, Katia R. M.; University of Sao Paulo Medical School. Urology Department. Laboratory of Medical Investigation.
Int. braz. j. urol ; 39(1): 95-102, January-February/2013. tab, graf
Article in English | LILACS | ID: lil-670368
ABSTRACT
Purpose Bladder cancer (BC) is the second most common malignancy of the urinary tract, with high mortality. The knowledge of the molecular pathways associated with BC carcinogenesis is crucial to identify new diagnostic and prognostic biomarkers. MicroRNAs (miRNAs) are short non-coding RNA molecules that play important roles in the regulation of gene expression by acting directly on mRNAs. miR-145 has been considered as a tumor suppressor, which targets the c-MYC, MUC-1 and FSCN1 genes. Our aim was to evaluate the expression profile of miR-145 in low-grade non-invasive and high-grade invasive bladder urothelial carcinomas. Materials and Methods We studied 30 specimens of low-grade, non-invasive pTa and 30 of pT2/pT3 high-grade invasive UC obtained by transurethral resection or radical cystectomy, followed over a mean time of 16.1 months. Normal controls were represented by five samples of normal bladder biopsy from patients who underwent retropubic prostatectomy to treat BPH. miRNA extraction and cDNA generation were performed using commercial kits. Analysis was performed by qRT-PCR, and miR-145 expression was calculated using the 2-∆∆ct method; we used RNU-43 and RNU-48 as endogenous controls. Results miR-145 was under-expressed in 73.3% and 86.7% of pTa and pT2/pT3, respectively, with expression means of 1.61 for the former and 0.66 for the last. There were no significant differences in miR-145 expression and histological grade, tumor stage, angiolymphatic neoplastic invasion and tumor recurrence. Conclusion miR-145 is under-expressed in low-grade, non-invasive and high-grade invasive urothelial bladder carcinoma and may play an important role in the carcinogenesis pathway, being an interesting candidate diagnostic marker. .
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / MicroRNAs Type of study: Evaluation studies / Prognostic study Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2013 Type: Article / Project document Affiliation country: Brazil

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell / MicroRNAs Type of study: Evaluation studies / Prognostic study Limits: Adult / Aged / Aged80 / Female / Humans / Male Language: English Journal: Int. braz. j. urol Journal subject: Urology Year: 2013 Type: Article / Project document Affiliation country: Brazil